The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies
Open accessAbstract
Gold compounds are a class of metallodrugs with great potential for cancer treatment. During the last two decades, a large variety of gold(I) and gold(III) compounds are reported to possess relevant antiproliferative properties in vitro against selected human tumor cell lines, qualifying themselves as excellent candidates for further pharmacological evaluation. The unique chemical properties of the gold center confer very interesting and innovative pharmacological profiles to gold-based metallodrugs. The primary goal of this review is to define the state of the art of preclinical studies on anticancer gold compounds, carried out either in vitro or in vivo. The available investigations of anticancer gold compounds are analyzed in detail, and particular attention is devoted to underlying molecular mechanisms. Notably, a few biophysical studies reveal that the interactions of cytotoxic gold compounds with DNA are generally far weaker than those of platinum drugs, implying the occurrence of a substantially different mode of action. A variety of alternative mechanisms were thus proposed, of which those involving either direct mitochondrial damage or proteasome inhibition or modulation of specific kinases are now highly credited. The overall perspectives on the development of gold compounds as effective anticancer drugs with an innovative mechanism of action are critically discussed on the basis of the available experimental evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Protein kinase C and lipid signaling for sustained cellular responses
Nishizuka, Y. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.7.7737456 · Cited by 2,499
Holmgren, A. (1985) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.54.070185.001321 · Cited by 1,951
Redox Regulation of Fos and Jun DNA-Binding Activity in Vitro
Abate, C., Patel, L., Rauscher, F. J., & Curran, T. (1990) · Science · doi:10.1126/science.2118682 · Cited by 1,573
Protein Kinase C Isotypes Controlled by Phosphoinositide 3-Kinase Through the Protein Kinase PDK1
Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., & Parker, P. J. (1998) · Science · doi:10.1126/science.281.5385.2042 · Cited by 1,110
Shaw, C. F. (1999) · Chemical Reviews · doi:10.1021/cr980431o · Cited by 990
Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate.
Nakanishi, H., Brewer, K. A., & Exton, J. H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54107-7 · Cited by 965
Hickey, J. L., Ruhayel, R. A., Barnard, P. J., Baker, M. V., Berners-Price, S. J., & Filipovska, A. (2008) · Journal of the American Chemical Society · doi:10.1021/ja804027j · Cited by 599
The thioredoxin system in cancer
Arnér, E. S. J., & Holmgren, A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.10.009 · Cited by 589
The Ubiquitin-Proteasome Pathway and Its Role in Cancer
Mani, A., & Gelmann, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.081 · Cited by 549
Human Placenta Thioredoxin Reductase
Gromer, S., Arscott, L. D., Williams, C. H., Schirmer, R. H., & Becker, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20096 · Cited by 536
Protein kinase C zeta subspecies from rat brain: its structure, expression, and properties.
Ono, Y., Fujii, T., Ogita, K., Kikkawa, U., Igarashi, K., & Nishizuka, Y. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.9.3099 · Cited by 498
Induction, Regulation, Degradation, and Biological Significance of Mammalian Metallothioneins
Miles, A. T., Hawksworth, G. M., Beattie, J. H., & Rodilla, V. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169168 · Cited by 429
Thioredoxin-dependent Redox Regulation of p53-mediated p21 Activation
Ueno, M., Masutani, H., Arai, R. J., Yamauchi, A., Hirota, K., Sakai, T., Inamoto, T., Yamaoka, Y., Yodoi, J., & Nikaido, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35809 · Cited by 428
Targeting the mitochondrial cell death pathway with gold compounds
Barnard, P. J., & Berners-Price, S. J. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2007.04.006 · Cited by 417
Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A., & Rigobello, M. P. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.12.021 · Cited by 415
Cell polarity in development and cancer
Wodarz, A., & Näthke, I. (2007) · Nature Cell Biology · doi:10.1038/ncb433 · Cited by 395
Dorn, G. W., Souroujon, M. C., Liron, T., Chen, C.-H., Gray, M. O., Zhou, H. Z., Csukai, M., Wu, G., Lorenz, J. N., & Mochly-Rosen, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12798 · Cited by 359
Milacic, V., Chen, D., Ronconi, L., Landis-Piwowar, K. R., Fregona, D., & Dou, Q. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3017 · Cited by 317
Ronconi, L., Marzano, C., Zanello, P., Corsini, M., Miolo, G., Maccà, C., Trevisan, A., & Fregona, D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0509288 · Cited by 314
Mirabelli, C. K., Johnson, R. K., Sung, C. M., Faucette, L. F., Muirhead, K. A., & Crooke, S. T. (1985) · PubMed · Cited by 295
Casini, A., Hartinger, C., Gabbiani, C., Mini, E., Dyson, P. J., Keppler, B. K., & Messori, L. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2007.11.003 · Cited by 267
Self-citationMarcon, G., Carotti, S., Coronnello, M., Messori, L., Mini, E., Orioli, P., Mazzei, T., Cinellu, M. A., & Minghetti, G. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010997w · Cited by 266
Self-citationMcKeage, M. J., Maharaj, L., & Berners-Price, S. J. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00048-6 · Cited by 243
Qin, J., Clore, G. M., Kennedy, W. P., Huth, J. R., & Gronenborn, A. M. (1995) · Structure · doi:10.1016/s0969-2126(01)00159-9 · Cited by 225
Raffel, J., Bhattacharyya, A. K., Gallegos, A., Cui, H., Einspahr, J. G., Alberts, D. S., & Powis, G. (2003) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(03)00068-4 · Cited by 219
The atypical protein kinase Cs: Functional specificity mediated by specific protein adapters
Moscat, J., & Diaz‐Meco, M. T. (2000) · EMBO reports · doi:10.1093/embo-reports/kvd098 · Cited by 217
Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions
Pia Rigobello, M., Messori, L., Marcon, G., Agostina Cinellu, M., Bragadin, M., Folda, A., Scutari, G., & Bindoli, A. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.020 · Cited by 213
Self-citationGold, the Noble Metal and the Paradoxes of its Toxicology
Merchant, B. (1998) · Biologicals · doi:10.1006/biol.1997.0123 · Cited by 202
Casini, A., Cinellu, M. A., Minghetti, G., Gabbiani, C., Coronnello, M., Mini, E., & Messori, L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060436a · Cited by 194
Self-citationWang, Y., He, Q.-Y., Sun, R. W.-Y., Che, C.-M., & Chiu, J.-F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2867 · Cited by 190
Grogan, T. M., Fenoglio-Prieser, C., Zeheb, R., Bellamy, W., Frutiger, Y., Vela, E., Stemmerman, G., Macdonald, J., Richter, L., Gallegos, A., et al. (2000) · Human Pathology · doi:10.1053/hp.2000.6546 · Cited by 188
Rackham, O., Nichols, S. J., Leedman, P. J., Berners-Price, S. J., & Filipovska, A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.022 · Cited by 186
Protein kinase C inhibitors as novel anticancer drugs
Jirousek, M. R., & Goekjian, P. G. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.12.2117 · Cited by 182
Atypical Protein Kinase Cι Plays a Critical Role in Human Lung Cancer Cell Growth and Tumorigenicity
Regala, R. P., Weems, C., Jamieson, L., Copland, J. A., Thompson, E. A., & Fields, A. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505402200 · Cited by 181
Induction of mitochondrial permeability transition by auranofin, a Gold(I)‐phosphine derivative
Rigobello, M. P., Scutari, G., Boscolo, R., & Bindoli, A. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704823 · Cited by 178
Thioredoxin reductase as a novel molecular target for cancer therapy
Nguyen, P., Awwad, R. T., Smart, D. D. K., Spitz, D. R., & Gius, D. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.04.028 · Cited by 172
Stallings‐Mann, M. L., Jamieson, L., Regala, R. P., Weems, C. R., Murray, N. R., & Fields, A. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3405 · Cited by 154
Gold(III) compounds as anticancer drugs
Gabbiani, C., Casini, A., & Messori, L. (2007) · Gold bulletin · doi:10.1007/bf03215296 · Cited by 142
Self-citationOmata, Y., Folan, M., Shaw, M., Messer, R. L. W., Lockwood, P. E., Hobbs, D. T., Bouillaguet, S., Sano, H., Lewis, J. B., & Wataha, J. C. (2006) · Toxicology in Vitro · doi:10.1016/j.tiv.2006.01.012 · Cited by 129
Chrysotherapy: a synoptic review
Eisler, R. (2003) · Inflammation Research · doi:10.1007/s00011-003-1208-2 · Cited by 123
Protein kinase Cι: Human oncogene, prognostic marker and therapeutic target
Fields, A. P., & Regala, R. P. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.015 · Cited by 120
Gabbiani, C., Casini, A., Luigi Messori, A., Guerri, A., Cinellu, M. A., Minghetti, G., Corsini, M., Rosani, C., Zanello, P., & Arca, M. (2008) · Inorganic Chemistry · doi:10.1021/ic701254s · Cited by 105
Self-citationAurothiomalate Inhibits Transformed Growth by Targeting the PB1 Domain of Protein Kinase Cι
Erdogan, E., Lamark, T., Stallings‐Mann, M. L., Jamieson, L., Pellechia, M., Thompson, E. A., Johansen, T., & Fields, A. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606054200 · Cited by 103
Dong, L., Zhang, R.-B., Langlais, P. R., He, H., Clark, M. C., Zhu, L. X., & Liu, F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8117 · Cited by 94
Gold(I) complexes as antimicrobial agents
Novelli, F., Recine, M., Sparatore, F., & Juliano, C. (1999) · Il Farmaco · doi:10.1016/s0014-827x(99)00019-1 · Cited by 84
Wang, Y., He, Q., Che, C., & Chiu, J. (2005) · PROTEOMICS · doi:10.1002/pmic.200402027 · Cited by 82
Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma
Lum, C. T., Yang, Z. F., Li, G. H., Sun, R. W., Fan, S. T., Poon, R. T. P., Lin, M. C. M., Che, C., & Kung, H. F. (2005) · International Journal of Cancer · doi:10.1002/ijc.21484 · Cited by 77
Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead
Wang, Y., He, Q., Sun, R. W., et al. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.10.034 · Cited by 76
Jellicoe, M. M., Nichols, S. J., Callus, B. A., Baker, M. V., Barnard, P. J., Berners‐Price, S. J., Whelan, J., Yeoh, G. C., & Filipovska, A. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn093 · Cited by 75
Goebel, C., Kubicka-Muranyi, M., Tonn, T., González, J., & Gleichmann, E. (1995) · Archives of Toxicology · doi:10.1007/s002040050198 · Cited by 66
Interactions of gold coordination complexes with DNA
Mirabelli, C. K., Sung, C.-M., Zimmerman, J. P., Hill, D. T., Mong, S., & Crooke, S. T. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90106-1 · Cited by 61
Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds
Engman, L., McNaughton, M., Gajewska, M., Kumar, S., Birmingham, A., & Powis, G. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200606000-00007 · Cited by 54
Wang, Y., He, Q., Che, C., Tsao, S. W., Sun, R. W., & Chiu, J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.11.024 · Cited by 47
Protein Kinase C in Disease: Cancer
Fields, A. P., & Gustafson, W. C. (2003) · Humana Press eBooks · doi:10.1385/1-59259-397-6:519 · Cited by 42
Crooke, S. T., & Mirabelli, C. K. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90482-5 · Cited by 41
The Activation of Gold Complexes by Cyanide Produced by Polymorphonuclear Leukocytes
Graham, G. G., & Kettle, A. J. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00031-8 · Cited by 37
Inhibition of Erythrocyte Selenium-Glutathione Peroxidase by Auranofin Analogues and Metabolites
Roberts, J. R., & Shaw, C. F. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00634-5 · Cited by 37
Cited by
Light-Emitting Self-Assembled Materials Based on d8 and d10 Transition Metal Complexes
Yam, V. W.-W., Au, V. K.-M., & Leung, S. Y.-L. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00074 · Cited by 1,661
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Chemical biology of anticancer gold(iii) and gold(i) complexes
Zou, T., Lum, C. T., Lok, C.-N., Zhang, J.-J., & Che, C.-M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00132c · Cited by 628
N-Heterocyclic carbene metal complexes in medicinal chemistry
Oehninger, L., Rubbiani, R., & Ott, I. (2013) · Dalton Trans. · doi:10.1039/c2dt32617e · Cited by 560
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Metadata
- Authors
- Nobili, S., Mini, E., Landini, I., Gabbiani, C., Casini, A., & Messori, L.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2009-07-24
- Volume
- 30
- Issue
- 3
- Pages
- 550-580
- ISSN
- 0198-6325 (ISSN-L)
- OpenAlex
- W2142620503
- Cited by
- 503
- References
- 58
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.